CellmAbs
CellMabs is a company focused on developing innovative solutions in the field of cell-based therapies and biopharmaceuticals. Their mission is to advance medical science through cutting-edge research and development.
Industries
Nr. of Employees
small (1-50)
Products
Antibody-Drug Conjugates (ADCs)
ADCs are therapies that link monoclonal antibodies to cytotoxic drugs, targeting cancer cells to minimize impact on normal tissues.
Bispecific T-Cell Engagers
These are therapies designed to engage two different targets simultaneously, one on T-cells and another on cancer cells, to direct the body’s immune system to attack tumors.
Cell Therapies
Treatments that use or modify immune cells to fight cancer, including engineering patients' own cells to better recognize and combat cancer cells.
Novel Humanized Monoclonal Antibodies
Monoclonal antibodies engineered to specifically recognize and bind to cancer cell antigens, enabling targeted therapy against solid tumors.
Research & Development
CellmAbs focuses on developing therapeutic modalities targeting cancer-specific glycans, partnering with other entities for innovative cancer treatments.
Antibody-Drug Conjugates (ADCs)
ADCs are therapies that link monoclonal antibodies to cytotoxic drugs, targeting cancer cells to minimize impact on normal tissues.
Bispecific T-Cell Engagers
These are therapies designed to engage two different targets simultaneously, one on T-cells and another on cancer cells, to direct the body’s immune system to attack tumors.
Cell Therapies
Treatments that use or modify immune cells to fight cancer, including engineering patients' own cells to better recognize and combat cancer cells.
Novel Humanized Monoclonal Antibodies
Monoclonal antibodies engineered to specifically recognize and bind to cancer cell antigens, enabling targeted therapy against solid tumors.
Research & Development
CellmAbs focuses on developing therapeutic modalities targeting cancer-specific glycans, partnering with other entities for innovative cancer treatments.